Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002338 · ClinicalTrials.gov registry record · Phase 1
The Safety and Effectiveness of 935U83 in HIV-Infected Patients
A Phase 1 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00002338 is a Phase 1 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 40 participants.
The verdict
NCT00002338, a Phase 1 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To assess the safety, tolerance, and steady-state pharmacokinetics of multiple oral doses of 935U83 administered to patients with HIV infection. To obtain preliminary evidence of antiretroviral activity of 935U83. To prospectively evaluate the emergence of in vitro drug resistance. To determine the effects of 935U83 dosing on CD4+ cell counts.
Interventions
- DRUG Raluridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002338
The ClinicalTrials.gov registry entry for NCT00002338 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raluridine is the first listed.
NCT00002338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002338 about?
NCT00002338 is a clinical study titled "The Safety and Effectiveness of 935U83 in HIV-Infected Patients". To assess the safety, tolerance, and steady-state pharmacokinetics of multiple oral doses of 935U83 administered to patients with HIV infection. To obtain preliminary evidence of antiretroviral activity of 935U83. To prospectively evaluate the emergence of in vitro drug resistance. To determine the ...
What is the current status of trial NCT00002338?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants.
What interventions are being tested in trial NCT00002338?
The interventions under investigation include: Raluridine (DRUG).
Who is sponsoring clinical trial NCT00002338?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.